Intra-Cellular Therapies Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,123	1,009	1,084	946.58
Revenue Growth (YoY)	18.61%	-6.86%	14.50%	-
Cost of Revenue	895.19	869.26	934.5	765.16
Gross Profit	227.57	140.2	149.3	181.42
Selling, General & Admin	110.71	119.66	118.01	105.73
Other Operating Expenses	-0.05	-2.56	4.05	0.05
Operating Expenses	110.65	117.1	122.06	105.78
Operating Income	116.91	23.1	27.24	75.63
Interest Expense	-0.34	-39.76	-19.65	-9.59
Interest & Investment Income	7.68	3.37	2.08	2.87
Earnings From Equity Investments	0.14	0.64	1.32	-
Currency Exchange Gain (Loss)	-22.17	-22.17	-7.81	-2.58
Other Non Operating Income (Expenses)	-6.05	-2.5	-34.22	6.01
EBT Excluding Unusual Items	96.17	-37.31	-31.05	72.34
Gain (Loss) on Sale of Investments	-0.45	-0.45	31.84	-12.4
Pretax Income	95.72	-37.76	0.79	59.94
Income Tax Expense	24.12	-7.19	-0.39	13.49
Earnings From Continuing Operations	71.6	-30.57	1.18	46.46
Minority Interest in Earnings	-0.25	-0.97	-0.22	-0.04
Net Income	71.35	-31.54	0.97	46.41
Net Income to Common	71.35	-31.54	0.97	46.41
Net Income Growth	53.72%	-	-97.91%	-
Free Cash Flow	89.1	79.25	-113.73	-9.64
Gross Margin	20.27%	13.89%	13.78%	19.16%
Operating Margin	10.41%	2.29%	2.51%	7.99%
Profit Margin	6.35%	-3.12%	0.09%	4.90%
Free Cash Flow Margin	7.94%	7.85%	-10.49%	-1.02%
EBITDA	134.54	38.84	38.45	90.75
EBITDA Margin	11.98%	3.85%	3.55%	9.59%
D&A For EBITDA	17.63	15.74	11.21	15.11
EBIT	116.91	23.1	27.24	75.63
EBIT Margin	10.41%	2.29%	2.51%	7.99%
Effective Tax Rate	25.20%	-	-	22.50%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.